Treats Parkinson’s disease (PD). ANDA 201970, held by Orbion Pharmaceuticals. Rasagiline Mesylate.
As of Nov 21, 2026, ANDA 201970 (Rasagiline Mesylate), held by Orbion Pharmaceuticals, was first approved by FDA on Mar 15, 2016, with 3 approved supplements and 0 published complete response letters.
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 15, 2016 | Original application | Approved | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Oct 16, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 2, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 2, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 15, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters